A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies

Clinical trial NCT07609862 · RECRUITING

Trial details

NCT number: NCT07609862
Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Mantle Cell Lymphoma (MCL)Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Waldenström Macroglobulinemia (WM)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Start date: 2026-07-14
Primary completion: 2029-06-30
Enrollment: 92

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.